Euromed’s pomegranate fruit extract ingredient Pomanox can positively modulate skin health and beauty-related parameters, according to new research.
An in vitro study conducted by EURECAT and published in the International Journal of Food Sciences found the Spanish company’s natural ingredient may reduce unaesthetic signs of skin ageing such as hyperpigmentation, skin dryness and loss of elasticity, by reducing melanogenesis and oxidative stress while modulating collagen and hyaluronic acid metabolism.
The results from this proof of concept, in vitro assay with human foreskin fibroblast cells, therefore suggest that Pomanox is a promising ingredient for nutricosmetic and beauty-from-within applications.
Euromed says Pomanox P30 is standardised to more than 50% total polyphenols and not less than 30% punicalagins α+β, making it an ideal candidate for skin ageing studies.
Multiple assays evaluated the effects of various concentrations of Pomanox on human fibroblast Hs68 cells under normal and UV-induced photoageing conditions. The inhibitory effects of Pomanox on tyrosinase activity were also investigated.
Analysis showed that under normal conditions, Pomanox significantly increased the collagen and hyaluronic acid metabolism. In cells exposed to UV, both preventive and regenerative treatments with Pomanox positively influenced hyaluronic acid metabolism and decreased ROS (Reactive Oxygen Species) levels.
A significant decrease in levels of MMP-1, the main inhibitor of collagen synthesis, was also verified. Finally, Pomanox showed a significant inhibitory effect on tyrosinase activity, thus potentially reducing hyperpigmentation by decreasing melanin synthesis.
Pomanox is a standardised pomegranate fruit extract obtained from pomegranates cultivated in Mediterranean regions of Spain through sustainable farming.
“In summary, the results highlight strong properties of Pomanox in the modulation of several skin health-associated parameters. A clinical study is now being prepared to further investigate and explore these insights,” said a Euromed spokeswoman.
